influenza
due
pandem
viru
abbrevi
viral
diseas
public
health
concern
caus
three
million
case
global
frequent
hospit
death
annual
season
influenza
one
lead
caus
admiss
intens
care
unit
icu
due
acut
respiratori
distress
syndrom
ard
sometim
requir
extracorpor
membran
oxygen
ecmo
support
oseltamivir
firstlin
treatment
infect
administ
oral
howev
pharmacokinet
properti
concern
resist
make
unsuit
patient
sever
lifethreaten
infect
unabl
take
oral
medic
bioavail
oseltamivir
extens
studi
patient
mechan
ventil
feed
via
nasogastr
tube
small
studi
investig
pharmacokinet
effect
three
patient
sever
influenza
therefor
therapeut
strategi
intraven
iv
use
zanamivir
may
benefit
intern
phase
random
control
trial
demonstr
iv
zanamivir
similar
antivir
efficaci
safeti
profil
oral
oseltamivir
patient
sever
influenza
infect
moreov
time
clinic
respons
differ
mg
mg
twice
daili
treatment
februari
committe
medicin
product
human
use
chmp
adopt
posit
opinion
author
market
iv
zanamivir
except
circumst
indic
treatment
complic
potenti
lifethreaten
influenza
b
viru
infect
adult
paediatr
patient
age
month
patient
influenza
viru
known
suspect
resist
antiinfluenza
medicin
product
zanamivir
andor
ii
antivir
medicin
product
treatment
influenza
includ
inhal
zanamivir
suitabl
individu
patient
case
seri
report
clinic
evolut
surviv
outcom
largest
number
patient
best
knowledg
underw
ecmo
support
treat
iv
zanamivir
anoth
case
report
describ
singl
patient
suffer
sever
respiratori
insuffici
treat
iv
zanamivir
prescrib
ecmo
influenza
season
year
four
patient
male
femal
age
year
admit
icu
ecmo
respiratori
support
due
sever
ard
relat
infect
patient
transfer
peripher
icu
ecmo
treatment
median
hospit
length
stay
day
rang
day
two
patient
immunecompromis
patient
due
relaps
hodgkin
lymphoma
patient
due
multipl
myeloma
patient
suffer
signific
underli
medic
condit
icu
admiss
four
patient
sequenti
organ
failur
assess
sofa
score
greater
predict
mortal
rate
higher
median
acut
physiolog
chronic
health
evalu
apach
score
rang
genom
detect
multiplex
polymeras
chain
reaction
pcr
perform
nasopharyng
swab
respiratori
panel
diagnost
itali
use
procedur
previous
report
besid
test
target
respiratori
panel
consist
sever
virus
adenoviru
coronaviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
human
rhinovirusenteroviru
influenza
influenza
influenza
influenza
b
parainfluenza
respiratori
syncyti
viru
three
bacteria
b
pertussi
c
pneumonia
pneumonia
summari
test
pouch
contain
dri
reagent
requir
specimen
extract
firststag
multiplex
pcr
individu
secondstag
realtim
pcr
oper
pouch
place
instrument
preprogram
run
initi
result
gener
use
amplif
melt
curv
data
neg
control
certifi
manufactur
food
drug
administr
fda
ce
approv
test
precaut
use
procedur
avoid
preanalyt
contamin
test
pouch
seal
nonreus
item
neg
control
run
period
evalu
perform
pcr
test
use
steril
collect
media
weekli
nasopharyng
swab
taken
pcr
qualit
analysi
detect
viral
clearanc
report
posit
neg
indic
presenc
absenc
viru
swab
specimen
respect
virus
detect
studi
viru
isol
attempt
ethic
approv
studi
grant
local
ethic
committe
patient
iv
zanamivir
administ
four
patient
compassion
basi
dosag
mg
twice
daili
instanc
iv
zanamivir
unavail
oral
oseltamivir
administ
dosag
mg
twice
daili
ensur
continu
antivir
treatment
patient
antivir
treatment
discontinu
followup
pcr
result
return
neg
genom
swab
specimen
patient
wean
ecmo
soon
intrapulmonari
shunt
mechan
ventil
discontinu
patient
abil
breath
spontan
assess
figur
depict
patient
daili
modif
sofa
score
white
blood
cell
count
ratio
arteri
partial
pressur
inspir
oxygen
fraction
obtain
ga
analysi
arteri
blood
sampl
tabl
summaris
main
result
patient
includ
superimpos
bacteri
infect
antibiot
treatment
median
time
ecmo
support
day
iqr
day
median
time
spent
mechan
ventil
day
iqr
median
length
stay
icu
day
iqr
median
durat
antivir
therapi
day
iqr
treatment
advers
reaction
side
effect
report
even
though
expect
surviv
patient
less
time
admiss
predict
sofa
score
clinic
condit
progress
improv
four
patient
surviv
clinic
condit
four
patient
progress
improv
iv
zanamivir
adjuv
therapi
despit
superimpos
multidrug
resist
infect
summaris
tabl
patient
diagnos
concomit
extensivelydrug
resist
xdr
acinetobact
baumannii
ab
pneumonia
suscept
colistin
carbapenemresist
klebsiella
pneumonia
crkp
treat
iv
colistin
ceftazidimeavibactam
day
patient
crkp
pneumonia
treat
twoweek
cours
ivaerosol
colistin
plu
meropenem
patient
suffer
crkp
pneumonia
secondari
bacteri
infect
treat
iv
colistin
plu
doubl
carbapenem
ertapenem
meropenem
day
patient
suffer
xdrab
pneumonia
secondari
bacteremia
treat
ivaerosol
colistin
tigecyclin
rifampicin
day
four
patient
demonstr
clinic
radiolog
evid
resolut
bacteri
lung
complic
bloodstream
bacteri
infect
resolut
defin
growth
bacteria
followup
blood
cultur
perform
day
previou
diagnosi
confirm
patient
respect
bloodstream
infect
determin
detect
bacteria
set
blood
cultur
collect
peripher
punctur
one
forearm
vein
patient
steril
condit
time
fever
spike
chill
leucocytosi
andor
septic
shock
exclud
presenc
catheterrel
bloodstream
infect
blood
sampl
also
collect
directli
indwel
cathet
despit
sever
lifethreaten
ill
expect
surviv
patient
less
time
admiss
predict
sofa
score
requir
life
support
treatment
ecmo
despit
subsequ
mdr
bacteri
superinfect
four
patient
end
studi
surviv
surviv
could
attribut
effect
iv
zanamivir
although
underestim
role
multidisciplinari
proactiv
treatment
approach
combin
effort
infecti
diseas
specialist
intensivist
microbiologist
employ
manag
patient
moreov
notic
none
four
case
treat
zanamivir
alon
receiv
oseltamivir
addit
zanamivir
therefor
latter
drug
contribut
treatment
effect
although
two
drug
administ
separ
may
also
addit
synergist
effect
prevent
emerg
isol
resist
one
drug
treat
preexist
resist
isol
effect
inde
virolog
potenc
antivir
combin
therapi
treatment
influenza
higher
oseltamivir
monotherapi
although
translat
greater
clinic
efficaci
moreov
studi
mice
model
show
increas
surviv
anim
infect
viru
treat
oseltamivirperamivir
combin
rather
oseltamivir
alon
surviv
benefit
confirm
immunedefici
mice
infect
influenza
viru
treat
oseltamivir
favipiravir
compar
treat
either
drug
howev
studi
oseltamivir
resist
prevent
combin
treatment
lastli
clinic
efficaci
superior
oseltamivirperamivir
combin
compar
oseltamivir
alon
patient
influenza
infect
conclus
possibl
administr
drug
continu
antivir
coverag
suppress
possibl
resist
viral
strain
increas
clinic
efficaci
hypothesi
requir
investig
zanamivir
prove
effect
particularli
one
patient
diagnos
sever
pneumonia
impair
gastrointestin
peristalsi
drug
malabsorpt
requir
life
support
measur
deep
sedat
neuromuscular
blockad
prone
posit
author
realis
viral
clearanc
despit
short
treatment
durat
day
earli
discontinu
zanamivir
find
similar
anoth
report
describ
excel
clinic
outcom
two
patient
suffer
influenza
myocard
refractori
cardiogen
shock
enter
drug
malabsorpt
treat
iv
zanamivir
author
studi
recommend
use
iv
zanamivir
enter
drug
malabsorpt
suspect
demonstr
exampl
use
paracetamol
absorpt
test
studi
demonstr
advantag
iv
zanamivir
oral
oseltamivir
one
studi
involv
mutat
viral
strain
influenza
mutat
patient
receiv
oseltamivir
prolong
viral
shed
delay
resolut
symptom
unlik
counterpart
receiv
zanamivir
show
iv
zanamivir
effect
oseltamivirresist
influenza
strain
anoth
studi
zanamivir
shown
reduc
lung
injuri
anim
model
probabl
due
antiinflammatori
properti
larg
retrospect
report
chantack
et
al
describ
characterist
patient
receiv
iv
zanamivir
retriev
food
drug
administr
fda
emerg
investig
new
drug
applic
databas
among
patient
confirm
diagnosi
infect
receiv
ecmo
due
sever
ard
although
studi
report
specif
clinic
outcom
patient
receiv
ecmo
author
report
surviv
patient
comparison
patient
studi
improv
clinic
surviv
upon
receiv
iv
zanamivir
howev
recogn
limit
studi
small
sampl
size
lack
control
may
make
observ
difficult
conclud
recommend
larg
sampl
size
studi
support
hypothesi
patient
immunecompromis
although
partial
explain
prolong
treatment
viru
persist
seem
offer
similar
explan
patient
underli
medic
condit
yet
receiv
treatment
rel
prolong
period
time
rang
day
case
viru
persist
treatment
prolong
viru
isol
run
genotyp
test
potenti
antivir
resist
neuraminidas
well
molecular
monitor
phenotyp
assay
recommend
inde
drugresist
oseltamivir
zanamivir
report
patient
influenza
howev
end
treatment
cours
zanamivir
oseltamivir
patient
achiev
clearanc
genom
respiratori
sampl
suggest
drug
resist
present
clinic
signific
conclus
find
studi
suggest
iv
zanamivir
good
therapeut
option
patient
sever
influenza
unabl
take
oral
aerosolis
drug
ecmo
mechan
ventil
recommend
prospect
random
trial
support
hypothesi
well
pharmacokinet
evalu
molecular
characteris
influenza
virus
help
delin
better
prevent
treatment
strategi
possibl
resist
strain
